What is ipamorelin?
Ipamorelin is a synthetic peptide that activates the ghrelin receptor and can stimulate the pituitary gland to release growth hormone. It belongs to a group called growth hormone secretagogues. Its human studies include a short hormone-response experiment and research into delayed bowel recovery after surgery.
Those studies answer different questions from the ones people often bring to a consultation: will it improve sleep, build muscle or help an injury recover? Understanding the distinction makes the research more useful.
Where the claim of selectivity comes from
The original 1998 work tested ipamorelin in rat pituitary cells, rats and swine. It stimulated GH release. In swine, it did not produce the ACTH and cortisol increases seen with the comparator peptides GHRP-2 and GHRP-6. That is the basis for describing it as selective.[1]
This was a valuable pharmacology finding. It was not a long-term human safety study. The often-repeated promise of GH release without cortisol problems takes an animal comparison further than it can support. Selectivity at a receptor or in an experiment does not establish freedom from side effects.
What the human hormone study found
A 1999 study gave short intravenous infusions to healthy men and measured ipamorelin and GH concentrations. Ipamorelin had a terminal half-life of about two hours. GH rose in a single episode, peaked at roughly forty minutes and then declined. This confirms that it can stimulate GH release in people.[2]
The study was about pharmacokinetics and hormone responses. It did not show improved strength, sleep, fat loss or injury healing. Its intravenous results also should not be treated as a demonstrated schedule or safety profile for repeated injections under the skin.
Why researchers tested bowel recovery
Ghrelin-receptor activity can also influence gut movement. In a rat model of postoperative ileus, a temporary slowing of the bowel after surgery, intravenous ipamorelin shortened the time to the first bowel movement. Repeated treatment improved additional measures, including food intake and fecal output; a single dose did not improve those later measures.[3]
That supported testing a practical patient outcome. The published phase 2 trial enrolled 117 adults undergoing bowel resection, with 114 included in the safety and main efficacy populations. Patients received intravenous ipamorelin or placebo for up to seven days.[4]
The median time from the first dose to a tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. The difference was not statistically significant, with a p value of 0.15. The authors reported no significant advantage in the main or secondary efficacy analyses. The numerical difference is worth reporting, but it does not establish that the treatment improved bowel recovery.[4]
What happened in the other registered studies?
A larger phase 2 study, NCT01280344, lists 320 participants and completed status. It investigated intravenous treatment after bowel surgery. As of November 9, 2026, its record had no posted results. Completion tells us the study ended; it does not tell us whether treatment worked or was safe.[5]
A newer observational record, NCT07717866, lists ipamorelin among possible components of a broader program for combat veterans. That program also includes other hormonal, psychological and device interventions. The registry has no posted results, and its design cannot isolate an ipamorelin benefit.[6]
What does the safety record show?
In the published bowel-surgery trial, treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. The authors described the treatment as generally well tolerated during this short exposure.[4]
FDA's detailed review adds necessary context. Serious adverse events occurred in 10 ipamorelin recipients and 9 placebo recipients. Two people in the ipamorelin group died after serious postoperative complications; whether the drug contributed was unclear. Low potassium and high blood glucose were reported more often with ipamorelin. These were ill surgical patients, so the findings neither prove drug causation nor establish safety for long-term use in other people.[7]
FDA also identified gaps in safety information for the subcutaneous route and concerns about peptide impurities and immune reactions. The available studies do not establish a long-term safety profile for repeated injections or combinations.[7]
What about muscle, sleep and CJC-1295 combinations?
The primary studies reviewed do not establish that ipamorelin improves muscle gain, sleep or injury recovery in people. Raising GH is a measured biological effect. Whether that translates into an improvement a person can feel or use needs its own clinical evidence.
CJC-1295 acts through a different receptor, which provides a rationale for studying the pair. We did not identify controlled human evidence that the combination improves these outcomes. The exact CJC formulation also matters: the long-acting DAC compound and products without DAC cannot be treated as interchangeable.
What the studies can tell us
Selective activity
Animal experiments support a particular pattern of hormone release, not a human safety guarantee.
Human GH response
A short intravenous study confirmed GH release in healthy men.
Bowel recovery
The published controlled trial did not show a significant efficacy advantage over placebo.
Other uses
Sleep, physique and recovery claims are not established by these human studies.
Approval and access are separate questions
Ipamorelin is not FDA-approved.[7] It is not included in the six-substance list in the October 2026 HHS peptide compounding policy. That policy concerns conditional enforcement discretion, not approval, and does not extend to ipamorelin merely because it is a peptide.[8]
The exact preparation, route and local requirements still need to be established. A prescription or a product-quality certificate does not demonstrate that a proposed treatment improves the outcome you want.
Making the conversation specific
Start with the problem
- What explains the symptoms or recovery difficulty?
- Which established options have evidence for that problem?
- What would count as a worthwhile improvement?
Check the match
- Was this exact product and route studied in people like me?
- Are the claimed benefits patient outcomes or hormone measurements?
- If several compounds are proposed, what supports that combination?
Plan the assessment
- How will my medical history and medicines be considered?
- Who will assess new symptoms or abnormal tests?
- When would the plan be reassessed if there is no useful benefit?
What to take away
Ipamorelin has human evidence for GH release and a published trial of bowel recovery that did not establish efficacy. Its selective activity in animals is interesting, but it cannot settle the benefits or safety of longer-term use, different routes or peptide combinations.
Questions people ask
Does ipamorelin increase growth hormone in humans?
Yes. A short intravenous study in healthy men measured a pulse of GH release after ipamorelin. It studied hormone responses and how the drug moved through the body, not improvements in muscle, sleep or recovery.
Does selective mean ipamorelin has no hormonal side effects?
No. The foundational selectivity experiments were largely in rats and swine. The cortisol and ACTH comparison was performed in swine. Those findings do not establish that repeated treatment in people is free of hormonal or other adverse effects.
Did the bowel-surgery trial show that ipamorelin works?
It did not establish efficacy. The published randomized trial found a numerically shorter time to a tolerated meal, but the difference was not statistically significant. Its main and secondary efficacy analyses showed no significant advantage over placebo.
Is ipamorelin approved under the new HHS peptide policy?
No. Ipamorelin is not FDA-approved and does not appear in the six-substance list in the October 2026 HHS policy. That policy describes conditional enforcement discretion for specified compounding, not approval of peptide drugs.
The evidence
Original studies, trial records and regulator documents used for this article. The study labels distinguish measured outcomes from plans and laboratory findings.
Sources checked November 9, 2026. This review covers the cited studies and current US regulator documents; it is not an exhaustive review of every jurisdiction.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Ipamorelin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.